Raymond James Financial
XERS icon

Raymond James Financial’s Xeris Biopharma Holdings XERS Stock Holding History

Raymond James Financial’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.21M Sell
208,273
-3,146
-1% -$20.9K ﹤0.01% 3727
2025
Q4 		$1.66M Buy
211,419
+6,206
+3% +$48.8K ﹤0.01% 3416
2025
Q3 		$1.67M Sell
205,213
-3,933
-2% -$26.1K ﹤0.01% 3307
2025
Q2 		$977K Buy
209,146
+28,830
+16% +$132K ﹤0.01% 3607
2025
Q1 		$990K Buy
180,316
+167,166
+1,271% +$675K ﹤0.01% 3501
2024
Q4 		$44.6K Buy
+13,150
New +$42.3K ﹤0.01% 4622

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial's XERS Position: Q1 2026 in Review

Raymond James Financial reduced its Xeris Biopharma Holdings (XERS) stake by 1.5% in Q1 2026, selling an estimated $20.9K and leaving 208,273 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3727.

Raymond James Financial first reported a position in XERS in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.67M in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Raymond James Financial held 208,273 shares of Xeris Biopharma Holdings worth $1.21M as of Q1 2026.
  • Raymond James Financial sold 3,146 Xeris Biopharma Holdings shares in Q1 2026, an estimated $20.9K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3727 holding.
  • Raymond James Financial first reported a position in Xeris Biopharma Holdings in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Xeris Biopharma Holdings position peaked at $1.67M in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.